Stock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses

Stock Track02-25

Corcept Therapeutics' stock experienced a significant after-hours plunge of 5.43% on Tuesday, following the release of its fourth-quarter financial results.

The company reported Q4 earnings per share of $0.20, which fell short of the consensus estimate of $0.27. Revenue for the quarter was $202.125 million, missing analyst expectations of $254.936 million. This represents a substantial revenue shortfall and contributed to a 21% decline in net income compared to the previous year.

Operational disruptions during a pharmacy transition impacted the company's ability to meet demand, according to the earnings report. Despite these challenges, Corcept provided forward guidance projecting full-year 2026 revenue between $900 million and $1,000 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100546116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100546116","market":"us","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses","media":"Stock Track","content":"<p>Corcept Therapeutics' stock experienced a significant after-hours plunge of 5.43% on Tuesday, following the release of its fourth-quarter financial results.</p><p>The company reported Q4 earnings per share of $0.20, which fell short of the consensus estimate of $0.27. Revenue for the quarter was $202.125 million, missing analyst expectations of $254.936 million. This represents a substantial revenue shortfall and contributed to a 21% decline in net income compared to the previous year.</p><p>Operational disruptions during a pharmacy transition impacted the company's ability to meet demand, according to the earnings report. Despite these challenges, Corcept provided forward guidance projecting full-year 2026 revenue between $900 million and $1,000 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 05:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corcept Therapeutics' stock experienced a significant after-hours plunge of 5.43% on Tuesday, following the release of its fourth-quarter financial results.</p><p>The company reported Q4 earnings per share of $0.20, which fell short of the consensus estimate of $0.27. Revenue for the quarter was $202.125 million, missing analyst expectations of $254.936 million. This represents a substantial revenue shortfall and contributed to a 21% decline in net income compared to the previous year.</p><p>Operational disruptions during a pharmacy transition impacted the company's ability to meet demand, according to the earnings report. Despite these challenges, Corcept provided forward guidance projecting full-year 2026 revenue between $900 million and $1,000 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1100546116","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100546116","pubTimestamp":1771970326,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corcept Therapeutics' stock experienced a significant after-hours plunge of 5.43% on Tuesday, following the release of its fourth-quarter financial results.The company reported Q4 earnings per share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"个股追踪|Corcept Therapeutics盘后暴跌5.43%因Q4盈利和营收不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics' stock experienced a significant after-hours plunge of 5.43% on Tuesday, following the release of its fourth-quarter financial results.The company reported Q4 earnings per share of $0.20, which fell short of the consensus estimate of $0.27. Revenue for the quarter was $202.125 million, missing analyst expectations of $254.936 million. This represents a substantial revenue shortfall and contributed to a 21% decline in net income compared to the previous year.Operational disruptions during a pharmacy transition impacted the company's ability to meet demand, according to the earnings report. Despite these challenges, Corcept provided forward guidance projecting full-year 2026 revenue between $900 million and $1,000 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100546116","isCrawlerRequest":true}